T-DM1在实体瘤研究中的进展及安全性评估
The Progress and Safety Assessment of T-DM1 in Solid Tumor Research
DOI: 10.12677/ACM.2021.116385, PDF,   
作者: 刘根利*：大连医科大学教学医院青岛市市立医院，山东 青岛；杨 雪, 李 玲, 袁胜利#：青岛大学附属青岛市市立医院，山东 青岛
关键词: HER-2；T-DM1；实体瘤；安全性；HER-2； T-DM1； Solid Tumor； Safety
摘要: 人表皮生长因子受体2 (HER2)基因的扩增在乳房、胃肠道、呼吸道、生殖道、泌尿道、皮肤和胎盘的上皮细胞的细胞膜上都可以检测到，在心脏和骨骼肌细胞上也可以检测到，HER-2过表达与侵略性表型和预后不良有关。因此，HER-2已成为许多抗癌治疗方法的重点。T-DM1是由曲妥珠单抗、细胞毒性药物DM1通过连接子偶联而成的抗体药物偶联物，具有靶向性和细胞毒杀伤双重抗肿瘤作用。在这篇综述中我们旨在总结有关T-DM1在各实体瘤研究中的进展及安全性和毒性的最新文献，有助于指导T-DM1的临床应用。
Abstract: The human epidermal growth factor receptor 2 (HER-2) expression can be detected on cell membranes of epithelial cells in the gastro-intestinal tract, respiratory tract, reproductive tract, urinary tract, skin, breast and placenta, but also on heart and skeletal muscle cells. HER-2 overexpression is associated with an aggressive phenotype and poor prognosis. HER-2, therefore, has become the focus of many cancer treatments. T-DM1 is an antibody drug conjugate formed by the trastuzumab and cytotoxic drug DM1, which has both targeting and cytotoxicity. In this review, we aim to summarize the latest literature on the research progress, safety and toxicity of T-DM1 in various solid tumors to help guide the clinical application of T-DM1.
文章引用：刘根利, 杨雪, 李玲, 袁胜利. T-DM1在实体瘤研究中的进展及安全性评估[J]. 临床医学进展, 2021, 11(6): 2663-2669. https://doi.org/10.12677/ACM.2021.116385

参考文献

[1] Krop, I.E., Kim, S.B., Gonzlez-Martin, A., et al. (2014) Trastuzumab Emtanaine versus Treatment of Physician HER2-Positive Advanced Breast Cancer (TH3RESA): A Randomised, Open-Lable, Phase 3 Trial. The Lancet Oncology, 15, 689-699. [Google Scholar] [CrossRef] 
[2] Lewis-Phillips, G., Li, G.D., Crocker, L., et al. (2008) Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate. Cancer Research, 68, 9280-9290. [Google Scholar] [CrossRef] 
[3] Krop, I.E., Lin, N.U., Blackwell, K., et al. (2015) Trastuzumab Emtansine (T-DM1) versus Lapatinib plus Capecitabine in Patients with HER2-Positive Metastatic Breast Cancer and Central Nervous System Metastases: A Retrospective, Exploratory Analysis in Emilia. Annals of Oncology, 26, 113-119. [Google Scholar] [CrossRef] [PubMed]
[4] Verma, S., Miles, D., Gianni, L., et al. (2012) Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer. The New England Journal of Medicine, 367, 1783-1791. [Google Scholar] [CrossRef] 
[5] Perez, E.A., Barrios, C., Eiermann, W., et al. (2017) Trastuzumab Emtansine with or without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2-Positive, Advanced Breast Cancer: Primary Results from the Phase III MARIANNE Study. Journal of Clinical Oncology, 35, 141-148. [Google Scholar] [CrossRef] 
[6] Montemurro, F., Ellis, P., Anton, A., et al. (2019) Safety of Trastuzumab Emtansine (T-DM1) in Patients with HER2-Positive Advanced Breast Cancer: Primary Results from the KAMILLA Study Cohort 1. European Journal of Cancer, 109, 92-102. [Google Scholar] [CrossRef] [PubMed]
[7] Hurvitz, S.A., Martin, M., Symmans, W.F., et al. (2016) Pathologic Complete Response (pCR) Rates after Neoadjuvant Tras-Tuzumab Emtansine (T-DM1) + Pertuzumab (P) vs Docetaxel + Carboplatin + Trastuzumab + P (TCHP) Treatment in Patients with HER2-Positive (HER2+) Early Breast Cancer (EBC) (KRISTINE). Journal of Clinical Oncology, 34, 500. [Google Scholar] [CrossRef] 
[8] Harbeck, N., Gluz, O., Christgen, M., et al. (2016) Final Analysis of WSG-ADAPT HER2+/HR+ Phase II Trial: Efficacy, Safety, and Predictive Markers for 12-Weeks of Neoad-Juvant T-DM1 with or without Endocrine Therapy versus Trastuzumab + Endocrine Therapy in HER2-Positive Hormone Receptorpositive Early Breast Cancer. Cancer Research, 76, Abstract nr S5-03. [Google Scholar] [CrossRef] 
[9] von Minckwitz, G., Huang, C.S., Mano, M.S., et al. (2019) Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. The New England Journal of Medicine, 380, 617-628.
[10] Uhlen, M., Fagerberg, L., Hallstrom, B.M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, A., Kampf, C., Sjostedt, E., Asplund, A., et al. (2015) Proteomics. Tissue-Based Map of the Human Proteome. Science, 347, 1260419. [Google Scholar] [CrossRef] [PubMed]
[11] Press, M.F., Cordon-Cardo, C. and Slamon, D.J. (1990) Expression of the HER-2/Neu Proto-Oncogene in Normal Human Adult and Fetal Tissues. Oncogene, 5, 953-962.
[12] Bang, Y.J., Van Cutsem, E., Feyereislova, A., Chung, H.C., Shen, L., Sawaki, A., et al. (2010) Trastuzumab in Combination with Chemotherapy versus Chemotherapy Alone for Treatment of HER2-Positive Advanced Gastric or Gastro-Oesophageal Junction Cancer (ToGA): A Phase 3, Open-Label, Randomised Controlled Trial. The Lancet, 376, 687-697. [Google Scholar] [CrossRef] 
[13] Waddell, T., Verheij, M., Allum, W., Cunningham, D., Cervantes, A., Arnold, D., et al. (2013) Gastric Cancer: ESMOESSO-ESTRO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Annals of Oncology, 24, vi57-vi63. [Google Scholar] [CrossRef] [PubMed]
[14] Thuss-Patience, P.C., Shah, M.A., Ohtsu, A., et al. (2017) Trastuzumab Emtansine versus Taxane Use for Previously Treated HER2-Positive Locally Advanced or Metastatic Gastric or Gastro-Oesophageal Junction Adenocarcinoma (GATSBY): An International Randomised, Open-Label, Adaptive, Phase 2/3 Study. The Lancet Oncology, 18, 640-653. [Google Scholar] [CrossRef] 
[15] Shah, M.A., Kang, Y.K., Thuss-Patience, P.C., et al. (2019) Biomarker Analysis of the GATSBY Study of Trastuzumab Emtansine versus a Taxane in Previously Treated HER2-Positive Advanced Gastric/Gastroesophageal Junction Cancer. Gastric Cancer, 22, 803-816. [Google Scholar] [CrossRef] [PubMed]
[16] Hotta, K., Fujiwara, Y., Matsuo, K., et al. (2007) Recent Improvement in the Survival of Patients with Advanced Non-Small-Cell Lung Cancer Enrolled into Phase III Trials of First-Line Systemic Chemotherapy. Cancer, 109, 939-948. [Google Scholar] [CrossRef] [PubMed]
[17] Hotta, K., Matsuo, K., Ueoka, H., Kiura, K., Tabata, M. and Tanimoto, M. (2004) Addition of Platinum Compounds to a New Agent in Patients with Advanced Non-Small-Cell Lung Cancer: A Literature Based Meta-Analysis of Randomised Trials. Annals of Oncology, 15, 1782-1789. [Google Scholar] [CrossRef] [PubMed]
[18] Lewis Phillips, G.D., Li, G., Dugger, D.L., et al. (2008) Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate. Cancer Research, 8, 9280-9290. [Google Scholar] [CrossRef] 
[19] Remillard, S., Rebhun, L.I., Howie, G.A. and Kupchan, S.M. (1975) Antimitotic Activity of the Potent Tumor Inhibitor Maytansine. Science, 189, 1002-1005. [Google Scholar] [CrossRef] [PubMed]
[20] Perera, S.A., Li, D., Shimamura, T., et al. (2009) HER2YVMA Drives Rapid Development of Adenosquamous Lung Tumors in Mice That Are Sensitive to BIBW2992 and Rapa-Mycin Combination Therapy. Proceedings of the National Academy of Sciences of the United States of America, 106, 474-479. [Google Scholar] [CrossRef] [PubMed]
[21] Weiler, D., Diebold, J., Strobel, K., Aebi, S. and Gautschi, O. (2015) Rapid Response to Trastu-Zumab Emtansine in a Patient with HER2-Driven Lung Cancer. Journal of Thoracic Oncology, 10, e16-e17. [Google Scholar] [CrossRef] 
[22] Ohashi, K., Hotta, K., Hirata, T., et al. (2017) Trastuzumab Emtansine in HER2+ Recurrent Metastatic Non-Small-Cell Lung Cancer: Study Protocol. Clinical Lung Cancer, 18, 92-95. [Google Scholar] [CrossRef] [PubMed]
[23] Hotta, K., Aoe, K., Kozuki, T., et al. (2018) A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 13, 273-279. [Google Scholar] [CrossRef] [PubMed]
[24] Li, B.T., Shen, R., Buonocore, D., et al. (2018) Ado-Trastuzumab Emtansine for Patients with HER2-Mutant Lung Cancers: Results from a Phase II Basket Trial. Journal of Clinical Oncology, 36, 2532-2537. [Google Scholar] [CrossRef] 
[25] Kobyakov, D.S., Avdalyan, A.M., Klimachev, V.V., Lazarev, A.F., Lushnikova, E.L. and Nepomnyaschikh, L.M. (2015) Non-Small Cell Lung Cancer: HER2 Oncogene Status. Arkhiv Patologii, 77, 3-9. (In Russian) [Google Scholar] [CrossRef] [PubMed]
[26] Barok, M., Joensuu, H. and Isola, J. (2014) Trastuzumab Emtansine: Mechanisms of Action and Drug Resistance. Breast Cancer Research, 16, Article No. 209. [Google Scholar] [CrossRef] [PubMed]
[27] Ishimine, Y., Goto, A., Watanabe, Y., et al. (2015) Loss of HER2 Positivity after Trastuzumab in HER2-Positive Gastric Cancer: Is Change in HER2 Status Significantly Frequent? Case Reports in Gastrointestinal Medicine, 2015, Article ID: 132030. [Google Scholar] [CrossRef] [PubMed]
[28] Janjigian, Y.Y., Riches, J.C., Ku, G.Y., et al. (2015) Loss of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in HER2-Overexpressing Esophagogastric (EG) Tumors Treated with Trastuzumab. Journal of Clinical Oncology, 33, 63 (abstr). [Google Scholar] [CrossRef] 

为你推荐